+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Testosterone Replacement Therapy Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4987060
  • Report
  • February 2020
  • Region: Global
  • 120 pages
  • Mordor Intelligence


  • AbbVie Inc
  • Allergan Plc
  • Bayer AG
  • Eli Lilly and Company
  • Endo Pharmaceuticals Inc
  • Ferring Pharmaceuticals
The Testosterone Replacement Therapy Market is expected to register a CAGR of 3.1% during the forecast period. Testosterone replacement therapy involves the administration of testosterone through creams/gels, patches, injections, gums/buccal adhesives or implants.

Testosterone is the primary male hormone responsible for the improvement of male sexual characteristics, spermatogenesis, and fertility. Insufficient production of testosterone causes erectile dysfunction. Erectile dysfunction occurs due to decreased testosterone production to overcome this testosterone replacement therapy is used to improve the problem. Testosterone deficiency or hypogonadism is a common problem among men between 40 and 79 years of age. As per a study published in the National Center for Biotechnology Information (NCBI), approximately 30% of men worldwide are affected by hypogonadism. According to Boston University School of Medicine, approximately 4 to 5 million men in the United States, are suffering from hypogonadism and low testosterone levels are commonly seen in older males. In addition, more than 60% of men over 65 years of age have free testosterone levels below the normal values of men between 30 to 35 years of age. In addition, a study published in the Indian Journal of Endocrinology and Metabolism in the year 2017, correlates the type 2 diabetes with hypogonadism and estimates that the prevalence of hypogonadism in type 2 diabetes patients to be approximately 20.7%. Furthermore, the prevalence rate of hypogonadism in patients with type 2 diabetes was moderate with highest number of patients belonging to age group 50–59 years. The rise in the incidence of testosterone deficiency, increase in geriatric population with high risk of testosterone deficiency and increasing awareness about testosterone substitute therapy are the key driving factors in testosterone replacement therapy market.

Key Market Trends

Topicals Segment is Expected to Hold a Major Market Share in the Testosterone Replacement Therapy Market
  • Topical testosterone is a drug that is applied to the skin to treat hypogonadism, a condition that prevents the body from making enough testosterone. Some of the topically applied testosterone drug forms are creams, gels, and patches.
  • As per the European Association of Urology 2016 report, the incidence of hypogonadism in middle-aged men, varied from 2.1% to 12.8%, in men aged 40-79 varied from 2.1% to 5.7%, in Europe which indicates hypogonadism is more prevalent in older men with obesity and with poor health status.
  • Topical (creams and gels) segment hold a significant market share in the testosterone replacement therapy market and is anticipated to show a similar trend over the forecast period due to advantages such as ease of application etc.
  • The rise in the incidence of testosterone deficiency, an increase in the geriatric population and increasing awareness about testosterone substitute therapy are the key driving factors in the topicals segment.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global testosterone replacement therapy market due to the increasing number of individuals suffering from hypogonadism and the rising geriatric population in this region. According to the study published in the European Association of Urology Journal in the year 2017, testosterone prescription trends in the United States registered an increase between 1.8 and 4-fold over the last two decades (1997 - 2017).

Competitive Landscape

The Testosterone Replacement Therapy Market is Consolidated competitive and consists of few major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are AbbVie Inc, Endo Pharmaceuticals Inc, Pfizer, Inc, Eli Lilly and Company, Allergan Plc, Bayer AG, Teva Pharmaceutical Industries Ltd, Ferring Pharmaceuticals, Acerus Pharmaceuticals Corporation and Mylan N.V.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown


  • AbbVie Inc
  • Allergan Plc
  • Bayer AG
  • Eli Lilly and Company
  • Endo Pharmaceuticals Inc
  • Ferring Pharmaceuticals
1.1 Study Assumptions
1.2 Scope of the Study




4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Incidence of Testosterone Deficiency
4.2.2 Increasing Novel Therapeutic Approaches
4.3 Market Restraints
4.3.1 Adverse Effects of the Testosterone Replacement Therapy
4.3.2 Stringent Regulations on Product Approval
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5.1 By Product Type
5.1.1 Injectables
5.1.2 Topicals
5.1.3 Others
5.2 Geography
5.2.1 North America United States Canada Mexico
5.2.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.2.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.2.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.2.5 South America Brazil Argentina Rest of South America


6.1 Company Profiles
6.1.1 AbbVie Inc
6.1.2 Endo Pharmaceuticals Inc
6.1.3 Pfizer, Inc
6.1.4 Eli Lilly and Company
6.1.5 Allergan Plc
6.1.6 Bayer AG
6.1.7 Teva Pharmaceutical Industries Ltd
6.1.8 Ferring Pharmaceuticals
6.1.9 Acerus Pharmaceuticals Corporation
6.1.10 Mylan N.V.

Note: Product cover images may vary from those shown
  • AbbVie Inc
  • Endo Pharmaceuticals Inc
  • Pfizer, Inc
  • Eli Lilly and Company
  • Allergan Plc
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd
  • Ferring Pharmaceuticals
  • Acerus Pharmaceuticals Corporation
  • Mylan N.V.
Note: Product cover images may vary from those shown